Đang chuẩn bị liên kết để tải về tài liệu:
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: Does sequence matter?

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Locally advanced or metastatic adenocarcinoma of the pancreas remains - despite the implementation of new chemotherapy protocols - a disease with short overall survival (OS). | Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas Does sequence matter

TÀI LIỆU LIÊN QUAN

Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nabpaclitaxel therapy in metastatic pancreatic cancer

A single-arm phase II study of nabpaclitaxel for patients with chemorefractory non-small cell lung cancer

Prognostic factors for survival with nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

A randomized phase II study of weekly nabpaclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: The AFUGEM GERCOR trial